PubRank

Sunwen Chou

Author PubWeight™ 43.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010 4.00
2 Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003 2.98
3 Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010 2.70
4 Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013 2.43
5 Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003 1.78
6 Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog 2007 1.29
7 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2006 1.28
8 Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003 1.28
9 Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008 1.23
10 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005 1.21
11 Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts. Virol J 2006 1.13
12 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003 1.10
13 The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011 1.10
14 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006 1.08
15 A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 2013 1.05
16 Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol 2013 1.04
17 Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010 1.01
18 Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002 0.99
19 Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J 2009 0.94
20 Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment. J Virol 2011 0.92
21 Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011 0.91
22 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2006 0.91
23 Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol 2014 0.87
24 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. Antimicrob Agents Chemother 2013 0.85
25 Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J 2006 0.85
26 Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res 2011 0.84
27 HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J Clin Virol 2004 0.84
28 Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology 2005 0.84
29 Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010 0.83
30 Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002 0.82
31 Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010 0.82
32 Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis. J Infect Dis 2002 0.81
33 Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol 2009 0.81
34 DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 2003 0.79
35 A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 2002 0.79
36 Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl 2003 0.79
37 Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients. Transfusion 2003 0.75